| Literature DB >> 26235422 |
Sarvenaz Metghalchi1, Padmapriya Ponnuswamy1, Tabassome Simon2, Yacine Haddad1, Ludivine Laurans1, Marc Clément3, Marion Dalloz1, Mélissa Romain1, Bruno Esposito1, Vincent Koropoulis1, Bruno Lamas4, Jean-Louis Paul5, Yves Cottin6, Salma Kotti2, Patrick Bruneval7, Jacques Callebert8, Hester den Ruijter9, Jean-Marie Launay8, Nicolas Danchin10, Harry Sokol4, Alain Tedgui1, Soraya Taleb11, Ziad Mallat12.
Abstract
Indoleamine 2,3-dioxygenase 1 (Ido1) is a rate-limiting enzyme that catalizes the degradation of tryptophan along the kynurenine pathway. Here, we show that Ido1 activity sustains an immunostimulatory potential through inhibition of interleukin (Il)10. In atherosclerosis, Ido1-dependent inhibition of Il10 translates into disease exacerbation. The resistance of Ido1-deficient mice to enhanced immune activation is broken in Ido1/Il10 double-deficient mice, which show exaggerated immune responses and develop severe spontaneous colitis. We demonstrate that Ido1 activity is required for the regulation of Il10 and that kynurenic acid (Kna), an Ido1-derived metabolite, is responsible for reduced Il10 production through activation of a cAMP-dependent pathway and inhibition of Erk1/2 phosphorylation. Resupplementation of Ido1-deficient mice with Kna limits Il10 expression and promotes atherosclerosis. In human atherosclerotic lesions, increased levels of Kna are associated with an unstable plaque phenotype, and its blood levels predict death and recurrent myocardial infarction in patients with coronary artery disease.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26235422 DOI: 10.1016/j.cmet.2015.07.004
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287